BALLERUP, Denmark--(BUSINESS WIRE)--NOT FOR UK USE – NOT INTENDED FOR UK MEDIA

丹麦巴勒鲁普——（商业新闻短讯）——不供英国使用——不供英国媒体使用

LEO Pharma A/S, a global leader in medical dermatology, has today presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). The data forms part of an expansive scientific program from LEO Pharma. Eight posters in total will be shared at the European Society of Contact Dermatitis (ESCD) congress, held in Dresden, Germany from the 4th to the 7th of September 2024..

LEO Pharma A/S是医学皮肤病学的全球领导者，今天介绍了一系列新的人群水平和医生报告的中重度慢性手部湿疹（CHE）的患病率，严重程度和治疗数据。这些数据构成了利奥制药公司广泛科学计划的一部分。2024年9月4日至7日，在德国德累斯顿举行的欧洲接触性皮炎学会（ESCD）大会上将分享总共八张海报。。

Four posters present data from CHECK (Chronic Hand Eczema epidemiology, Care, and Knowledge of real-life burden), a large multinational, prevalence study of CHE.1-4 CHECK was conducted among 60,131 adult participants from the general population in France, Spain, Italy, Germany, Canada, and the UK.1-4 The data from CHECK is supported by the findings in the RWEAL (Real-World trEatment & mAnagement of chronic hand eczema in cLinical practice) study, which examined the physician-reported treatment patterns in CHE.

四张海报展示了CHECK（慢性手部湿疹流行病学，护理和现实生活负担知识）的数据，这是一项大型跨国CHE患病率研究.1-4 CHECK在法国，西班牙，意大利，德国，加拿大和英国的60131名成年参与者中进行。CHECK的数据得到了RWEAL（临床实践中慢性手部湿疹的现实世界治疗和管理）研究的结果的支持，该研究检查了医生报告的CHE治疗模式。

It was a medical chart review of 1,939 patients, involving 292 physicians from Canada, Germany, France, Italy, Spain, and the UK.5 Historically, data relating to the prevalence of CHE and treatment options has been limited.6,7.

这是对1939名患者的医学图表审查，涉及来自加拿大，德国，法国，意大利，西班牙和英国的292名医生。从历史上看，与CHE患病率和治疗选择有关的数据有限[6,7]。

“It is a privilege to present the results from the largest real-world studies LEO Pharma has ever completed,” said Kreesten Meldgaard Madsen, LEO Pharma’s Chief Development Officer. “Our findings from the CHECK study are supported by the physician-reported outcomes of the RWEAL study and for the first time at this scale, the data from both studies can show the needs among people living with this debilitating disease, and the immense impact it can have on quality of life.”.

LEO Pharma首席开发官Kreesten Meldgaard Madsen表示：“很荣幸能够展示LEO Pharma有史以来完成的最大规模的现实研究结果。”。“我们的CHECK研究结果得到了医生报告的RWEAL研究结果的支持，这两项研究的数据首次以这种规模显示了患有这种衰弱性疾病的人的需求，以及它对生活质量的巨大影响。”。

CHECK results: Prevalence of CHE in adults and data from patient-reported outcomes

检查结果：成人CHE患病率和患者报告结果的数据

One poster shows that CHE is a common skin disease, with 5.6% of study participants self-reporting CHE in the last 12 months. Overall, 4.7% of participants reported physician-diagnosed CHE.1

一张海报显示，CHE是一种常见的皮肤病，在过去的12个月中，有5.6%的研究参与者自我报告了CHE。总体而言，4.7%的参与者报告了医生诊断的CHE。1

An additional CHECK poster concludes that CHE is a burdensome disease that can have a direct impact on occupation, leisure time, and overall daily life of individuals with CHE. Among participants who self-reported CHE (n=2,330), one in five (21.5%) attribute their disease to their occupation, and almost one in three (30.3%) to their household/leisure activities.2.

另一张检查海报得出结论，CHE是一种负担沉重的疾病，可能直接影响CHE患者的职业，休闲时间和整体日常生活。在自我报告CHE（n=2330）的参与者中，五分之一（21.5%）将其疾病归因于职业，近三分之一（30.3%）归因于家庭/休闲活动。

“The heavy burden of chronic hand eczema is well understood but prevalence has been historically understudied in the general population,” said Professor Sonja Molin, chair of the Division of Dermatology, Queen’s University and lead author. “Large-scale, multinational studies like CHECK provide powerful insights to help us better understand this debilitating disease.”.

女王大学皮肤病学系主任、主要作者索尼娅·莫林（SonjaMolin）教授说：“人们对慢性手部湿疹的沉重负担有着很好的理解，但从历史上看，普通人群的患病率一直没有得到充分的研究。”。“像CHECK这样的大规模跨国研究提供了强有力的见解，可以帮助我们更好地了解这种使人衰弱的疾病。”。

Further analysis assessed participants with physician-reported CHE (n=1,948). It showed that, despite the majority of participants receiving treatment, symptoms persisted across all treatment groups, indicating an unmet treatment need in this population.3

进一步的分析评估了医生报告的CHE（n=1948）的参与者。研究表明，尽管大多数参与者接受了治疗，但所有治疗组的症状持续存在，表明该人群的治疗需求未得到满足。3

RWEAL results: Data from physician-reported outcomes

RWEAL结果：来自医生报告结果的数据

The RWEAL poster presented at ESCD found that the use of medium, high or ultra-high potency topical corticosteroids (TCS) was reported in more than 90% of moderate to severe CHE patients. More than one-in-four patients (27.4%) with moderate to severe CHE had progressed to phototherapy or systemic therapy, oral immunosuppressants, and biologics.5.

。超过四分之一的中度至重度CHE患者（27.4%）进展为光疗或全身治疗，口服免疫抑制剂和生物制剂。

Finally, in addition to the new data presented at the congress, three encore posters were also presented on the latest phase 3 clinical trial results from the DELTA 1, 2, and 3 studies. A symposium titled “Dear Diary: Chronic Hand Eczema in the patients’ words*” is also scheduled to take place on the 5th of September to shed more light on the CHE experience through the words of patients.

最后，除了在大会上提供的新数据外，还提供了三张关于DELTA 1、2和3研究的最新3期临床试验结果的安可海报。一个名为“亲爱的日记：患者话语中的慢性手部湿疹*”的研讨会也计划于9月5日举行，以通过患者的话语来揭示CHE的经历。

8-10.

8-10.

About Chronic Hand Eczema

关于慢性手部湿疹

Chronic hand eczema (CHE) is defined as hand eczema (HE) that lasts for more than three months or relapses twice or more within a year.11,12 HE is the most common skin disorder of the hands13 with a one-year prevalence rate of approximately 9%.14 In a substantial number of patients, HE can develop into a chronic condition.13 CHE is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.15.

慢性手部湿疹（CHE）被定义为持续三个月以上或一年内复发两次或两次以上的手部湿疹（HE）[11,12]。他是手部最常见的皮肤病[13]，一年患病率约为9%[14]。在相当多的患者中，他可以发展为慢性病[13]。CHE是一种以瘙痒和疼痛为特征的波动性疾病，患者可能会出现红斑，鳞屑，苔藓化，角化过度，水泡，水肿和手和手腕上的裂缝等症状。

CHE has been shown to cause psychological and functional burdens that impact patient quality of life,16 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities, and suffering disruption in their daily life due to the condition.17 Furthermore, work and earning potential have also been shown to be impacted by the burden of living with CHE.18.

CHE已被证明会造成影响患者生活质量的心理和功能负担[16]，大约70%患有严重CHE的人承认在日常活动中存在问题，并且由于这种情况而在日常生活中受到干扰[17]。此外，工作和收入潜力也被证明受到与CHE一起生活的负担的影响。

About the CHECK study

关于支票研究

CHECK (Chronic Hand Eczema epidemiology, Care, and Knowledge of real-life burden) is a population-based study which recruited (n=60,131) participants in six countries including Canada, Germany, France, Italy, Spain, and the UK aged 18-69 via online panels. Participants were representative of the general population regarding sex, age, region, employment status, urban/rural setting, and, for the UK, ethnicity.1-4.

CHECK（慢性手部湿疹流行病学，护理和现实生活负担知识）是一项基于人群的研究，通过在线小组招募了加拿大，德国，法国，意大利，西班牙和英国等六个国家（n=60131）的参与者，年龄在18-69岁之间。参与者代表了普通人群的性别，年龄，地区，就业状况，城市/农村环境，以及英国的种族。

The objective of the CHECK study was to investigate and analyze self-reported disease severity, symptoms, and treatments in CHE. Furthermore, the study estimated and described the prevalence according to key socio-demographic characteristics. Association and impact of CHE on exposures and occupation or household/leisure activities were also investigated.1-4.

CHECK研究的目的是调查和分析CHE中自我报告的疾病严重程度，症状和治疗方法。此外，该研究根据关键的社会人口特征估计和描述了患病率。还调查了CHE对暴露和职业或家庭/休闲活动的关联和影响。

About the RWEAL study

关于RWEAL研究

The RWEAL (Real-World trEatment & mAnagement of chronic hand eczema in cLinical practice) study is a medical chart review which involved (n=292) physicians from Canada, Germany, France, Italy, Spain, and the UK. Patients ≥18 years of age with moderate to severe CHE treated with TCS in the past 12 months, or with TCS contraindication, were randomly selected from physician’s overall caseload in the preceding 12 months.

RWEAL（临床实践中慢性手部湿疹的现实世界治疗和管理）研究是一项医学图表审查，涉及来自加拿大，德国，法国，意大利，西班牙和英国的292名医生。从过去12个月的医生总体病例中随机选择≥18岁的中重度CHE患者，在过去12个月内接受TCS治疗，或有TCS禁忌症。

Data on treatments used in the 12 months prior to the last visit was collected and analyzed descriptively.5.

收集最后一次就诊前12个月内使用的治疗数据并进行描述性分析。

The objective of the RWEAL study was to investigate treatment patterns in patients with moderate to severe CHE over 12 months, focusing on topical corticosteroid (TCS) therapy. 5

RWEAL研究的目的是调查12个月内中度至重度CHE患者的治疗模式，重点是局部皮质类固醇（TCS）治疗。5

About LEO Pharma

关于LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities.

利奥制药（LEO Pharma）是一家全球性公司，致力于提高护理标准，造福皮肤病患者及其家人和社会。LEO Pharma成立于1908年，由LEO基金会拥有多数股权。LEO Pharma致力于数十年的研究和开发，以推动皮肤病学的发展。如今，该公司为所有严重疾病提供了广泛的治疗方法。

LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion..

利奥制药（LEO Pharma）总部位于丹麦，拥有4200人的全球团队，为全球数百万患者提供服务。2023年，该公司净销售额为114亿丹麦克朗。。

Disclaimers

免责声明

*Accounts from actual patients living with CHE.

*来自实际患有CHE的患者的账户。

References

参考文献

Apfelbacher C, Bewley A, Molin S, et al. Prevalence of Chronic Hand Eczema in adults: A cross-sectional multi-national study of 60,000 respondents in the general population. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #3.

Apfelbacher C，Bewley A，Molin S等。成人慢性手部湿疹的患病率：一项针对60000名普通人群的横断面多国研究。在2024年欧洲接触性皮炎学会（ESCD）大会上发表；2024年9月4日至7日；德国德累斯顿。海报展示#3。

Crepy MN, Molin S, Gimenez-Arnau AM, et al. Exploring the relationship between Chronic Hand Eczema occupation, and household/leisure activities. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #19

Crepy MN，Molin S，Gimenez Arnau AM等。探索慢性手部湿疹职业与家庭/休闲活动之间的关系。在2024年欧洲接触性皮炎学会（ESCD）大会上发表；2024年9月4日至7日；德国德累斯顿。海报展示#19

Molin S, Fargnoli MC, Crepy MN, et al. Self-reported disease severity and treatment of Chronic Hand Eczema from the CHECK study – A multinational study in six countries. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #64.

Molin S，Fargnoli MC，Crepy MN等。CHECK研究中自我报告的疾病严重程度和慢性手部湿疹的治疗-一项在六个国家进行的多国研究。在2024年欧洲接触性皮炎学会（ESCD）大会上发表；2024年9月4日至7日；德国德累斯顿。海报展示#64。

Molin S, Le Calve P, Daccache A, et al. Self-reported disease severity and treatment of Chronic Hand Eczema in Germany. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #65

Molin S，Le Calve P，Daccache A等。德国慢性手部湿疹的自我报告疾病严重程度和治疗。在2024年欧洲接触性皮炎学会（ESCD）大会上发表；2024年9月4日至7日；德国德累斯顿。

Gimenez-Arnau AM, Bewley A, Apfelbacher C, et al. Physician-reported treatment patterns in Chronic Hand Eczema – results from the multinational RWEAL medical chart review. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #27.

Gimenez-Arnau AM，Bewley A，Apfelbacher C等人。医生报告了慢性手部湿疹的治疗模式-多国RWEAL医学图表审查的结果。在2024年欧洲接触性皮炎学会（ESCD）大会上发表；2024年9月4日至7日；德国德累斯顿。海报展示#27。

Quaade AS, Simonsen AB, Halling AS, Thyssen JP, Johansen JD. Prevalence, incidence, and severity of hand eczema in the general population - A systematic review and meta-analysis. Contact Dermatitis. 2021;84(6):361-374.

Quaade AS，Simonsen AB，Halling AS，Thyssen JP，Johansen JD。一般人群手部湿疹的患病率，发病率和严重程度-系统评价和荟萃分析。。2021年；84（6）：361-374。

Christoffers WA, Coenraads PJ, Svensson Å, et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019;4(4):CD004055.

Christoffers WA，Coenraads PJ，SvenssonÅ等。手部湿疹的干预措施。Cochrane数据库系统修订版2019；4（4）：CD004055。

Bauer A, Schuttelaar ML, Baranowski K, et al. Delgocitinib cream reduces itch and pain in adults with moderate to severe Chronic Hand Eczema: pooled analyses of the Phase 3 DELTA-1 and -2 trials. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany.

Bauer A，Schuttelaar ML，Baranowski K等人。Delgocitinib乳膏可减轻中度至重度慢性手部湿疹患者的瘙痒和疼痛：3期DELTA-1和-2期试验的汇总分析。在2024年欧洲接触性皮炎学会（ESCD）大会上发表；2024年9月4日至7日；德国德累斯顿。

Poster presentation #8.

海报展示#8。

Schuttelaar ML, Bissonnette R, Worm M, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema: pooled results of the Phase 3 DELTA-1 and -2 trials. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany.

Schuttelaar ML，Bissonnette R，Worm M等。delgocitinib乳膏治疗成人中度至重度慢性手部湿疹的疗效和安全性：3期DELTA-1和-2期试验的汇总结果。在2024年欧洲接触性皮炎学会（ESCD）大会上发表；2024年9月4日至7日；德国德累斯顿。

Poster presentation #83.

海报展示#83。

Molin S, Gooderham M, Bissonnette R, et al. Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with Chronic Hand Eczema: results of the Phase 3 open-label extension DELTA-3 trial. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany.

Molin S，Gooderham M，Bissonnette R等。delgocitinib乳膏在慢性手部湿疹成人中长达36周的长期安全性和有效性：3期开放标签扩展DELTA-3试验的结果。在2024年欧洲接触性皮炎学会（ESCD）大会上发表；2024年9月4日至7日；德国德累斯顿。

Poster presentation #63.

海报展示#63。

Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360.

Lynde C，Guenther L，Diepgen TL等。加拿大手部皮炎管理指南。J Cutan Med Surg。2010；14（6）：267-284。勘误表：J Cutan Med Surg。2011年11月至12月；15（6）：360。

Diepgen TL, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015 Jan;13(1):e1–22.

Diepgen TL等人。手部湿疹的诊断、预防和治疗指南。J Dtsch皮肤病杂志。2015年1月；13（1）：e1-22。

Bissonnette R, et al. Redefining treatment options in chronic hand eczema (CHE). JEADV. 2010;24;1–20.

Bissonnette R等人。重新定义慢性手部湿疹（CHE）的治疗选择。杰德。2010年；24；1–20。

Thyssen, et al. The epidemiology of hand eczema in the general population – prevalence and main findings. Contact Dermatitis. 2010;62:75-87.

Thyssen等人。普通人群手部湿疹的流行病学-患病率和主要发现。。2010年；62:75-87。

Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378.

Thyssen JP，Schuttelaar MLA，Alfonso JH等。手部湿疹的诊断、预防和治疗指南。。2022年；86（5）：357-378。

Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706.

Grant L，Seiding Larsen L，Burrows K等。基于对患者和专家皮肤科医生的定性访谈，开发慢性手部湿疹（CHE）的概念模型。高级Ther。2020年；37（2）：692-706。

Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168.

Cortesi PA，Scalone L，Belisari A等。局部强效皮质类固醇标准治疗难治的严重慢性手部湿疹患者的成本和生活质量。。2014年；70（3）：158-168。

Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626.

。荷兰普通人群手部湿疹的患病率和严重程度：生命线队列研究中的横断面问卷研究。性病学报。2022年；102:adv00626。

MAT-76002 September 2024

MAT-76002 2024年9月